Biosciences, an innovative developer of molecular diagnostic tests,
today announced the company will present data at two key scientific
conferences this month on the latest in bladder cancer advancements
using next-generation sequencing for multiple biomarker detection.
Predictive Biosciences will present two talks at the upcoming American
Association for Cancer Research (AACR) Annual Meeting to be held April 6
– 10, 2013 in Washington, DC. The first presentation entitled, “Next-Gen
deep amplicon sequencing of TP53 complements FGFR3 for the detection of
bladder cancer-related mutations” will be given by Anthony P.
Shuber, chief technology officer. The second presentation entitled, “Detection
of bladder cancer-associated gene methylation using next-gen bisulfite
sequencing” will be given by Cecilia Fernandez, director of
research. Both presentations will take place on Sunday, April 7, 2013,
from 1:00 p.m. - 5:00 p.m.
The company will also present at the 45th Annual Oak Ridge
Conference, “Emerging Technologies for 21st Century
Diagnostics” to be held April 18 – 19, 2013 in Baltimore, MD. Anthony P.
Shuber will present on Friday, April 19, 3:10 – 3:25 p.m. EST in a
session entitled “Biomarkers: Buyer Beware”. His talk will discuss the
updates made to the company’s next-generation sequencing assay for
bladder cancer, which includes the ability to analyze protein and DNA
simultaneously on a next-generation sequencing platform.
“As the first company to introduce molecular diagnostic tests into
routine clinical use using next-generation sequencing, we continue to
leverage our proprietary technology based on the simultaneous detection
of DNA and protein biomarkers. In addition to what we are presenting at
these key scientific conferences, we are developing additional molecular
tests applying our novel approaches to other cancers such as prostate
cancer,” said Anthony P. Shuber.
About Predictive Biosciences
Predictive Biosciences develops novel molecular diagnostic cancer assays
and provides molecular pathology services for urology-based practices.
Leveraging a portfolio of patented biomarkers and clinical approaches,
the company has built a unique portfolio of assays for cancer
management, first targeted at bladder and prostate cancer. Predictive
Biosciences’ new approach to molecular testing analyzes multiple
biomarkers (DNA and protein) together in a single test to determine
disease state. The company’s CertNDx™ tests enable physicians to
accurately detect cancer. Headquartered in Lexington, MA, the company is
backed by leading investors, including Flybridge Capital Partners,
Highland Capital Partners, Kaiser Permanente Ventures, New Enterprises
Associates, Inc. (NEA) and ProQuest Investments. For additional
information, please visit www.predictivebiosci.com.